Relevant Studies Sample Clauses

Relevant Studies. As soon as reasonably practicable, the Members shall inform the Coordinator of any relevant existing study legally owned by them and other available studies of which they are aware or Core Data concerning the Substance. On the basis of competent analysis respecting the usability of the studies made available for registration in accordance with the previous paragraph, the Coordinator shall prepare a proposal for their financial value on the basis of the valuation rules indicated in Appendix 6. This proposal shall be agreed and adopted by the steering committee.
Sample 1
AutoNDA by SimpleDocs
Relevant Studies. Research using the whatsApp application has been used by provious research. With the existence of provious research, it can be show that whatsApp application can be used as a media for student learning, evidence of success from this has been proven from several researchers including: The first thesis was written by Xxxxxx Xxxxx Xxxxxx (2006) Students' Perceptions of Using Whatsapp as a Learning Tool in ESL Classrooms. She discussed that using whatsApp is very important in helping students learn the language better and improve their proficiency in using English. The difference between Xxxxxx Xxxxx Xxxxxx and this research is shefocused on students' perceptions of the use of whatsApp as a learning tool in the ESL classroom and whether or not, whatsApp is important to use in the future in helping students improve their language learning and the instrument she used was questionnaires. But in this study only focused on students' perception on the use of whatsapp in teaching English and use instrument interview and documentation to retrieve data. The similary of the two studies is to use the whatsApp application to help students improve English learning. The second thesis was written by Xxxx X. Xxxxx (2017) Using WhatsApp to Enhance Students’ Learning of English Language “ Experience to Share”. She discussed using whatsApp to enhance students' enthusiasm and learning, using whatsApp to help students develop skills in English, enriching them in their vocabulary and learning from the mistakes of their partners. The difference between Xxxx X. Xxxxx'x thesis and this research is supported using whatsApp to enhance students learning and enthusiasm, using whatsApp helped students to develop English skills, enriched their vocabulary and learn from their mates mistakes, although the study laid out some disadvantages of the experience such as preparing the materials and having discipline in the group. The similary of the two studies have in common is that using whatsApp helps students develop English language skills. The third thesis was written by Xxxxxxx Xxxxxxxxxx Xxxxxxx (2018) Perceptions of students’ on the Use of WhatsApp in Teaching Methods of English as Second Language. He discussed using whatsApp presents itself as one of the inventive teaching methods that can attract students and provide them with opportunities for further learning. WhatsApp increases helps students to work smarter and more effectively. The difference between Xxxxxxx Xxxxxxxxxx Xxxxxxx’s thes...
Sample 1
Relevant Studies. Several researchers have conducted study about using WhatsApp in study. (Xxxxxxxx et al., 2018) aimed to examine the use of WhatsApp application to teach writing of recount text. The result of this research is showed that the use of WhatsApp application is significant improvement on student’s writing skill. Xxxxxx (2015) identified the effectiveness of using WhatsApp messenger as one of mobile learning techniques to develop students’ writing skill at Saudi private university students. There are 30 students participated in the study where the experimental group ( n = 15) used WhatsApp to develop their writing skills and the contrl group (n = 15 ) was though their writing through the prescribed book. The result of this research showed that the students who are though using WhatsApp had significant effect on their writing skill, particularly on their sentence structure. (Xxxxx, 2019) the research found out whether or not the effectiveness of using WhatsApp as pedagogical tool to enhance EFL learners reading and writing skill at Aden university southern yemen. The result of this research showed that the students who are though WhatsApp very effective to developing students’ motivation to improve their reading and writing skill. Particularly in grammar, vocabularies, reading comprehension and writing. A research conducted by xxxxxxx and xxxxx entitled the influence of WhatsApp in teaching toward student’s writing recount performance. This study consisted of 30 students of control class and experimental class. The result showed that there were significant difference between student’s scores of control class and experimental class. In conclusion, it can be concluded that WhatsApp influence significantly on student’s writing performance. The researcher in this research found out the something new that compared the result between using whatsapp as a learning tool on students’ writing ability at MA Laboratorium Kota jambi have significant Effect and significant difference on students’ writing than the using zoom as a learning tool.
Sample 1
Relevant Studies. There are five studies that related to my recent study. The first study is the study from Tamimi(2009). “Motivation and Attitude Towards Learning English”. A Study of PetroleumEnginerring Undergraduates At-HadramoutUniversity of Science and Technology” This study investigated students‟ motivation, integrative motivation and personal motivation based on Xxxxxxx‟s (1985) and Copper and Xxxxxxx‟s (1977) . A questionnaire and interviews were used for data collection. For the students‟ motivation, the findings showed the subjects‟ greater support of instrumental reasons for learning the English language including utilitarian and academic reasons. Personal reasons were also regarded as important motivies by the students. However, regarding the integrative reasons, the result provided evidence that learning English as part of the culture of it‟s people had the least impact in students‟ attitude revealed that most of students had positive attitude towards the social value and educational status of English. The second study is the study from Xxxxxxxx. Khoir (2014) entitled “The Language Attitude of Students of English Department UIN SunanKalijagaTowards English”. He applied the five point Likert Scale and semi-structured Interview. The result showed that the respondent to have positive attitude towards English. They know the importance of English in globalization era, learn English proudly, and intend to practice English well and correctly and for respondents‟ orientation in learning English, they are influenced by both instrumental orientation and integrative orientation. Discussion interview
Sample 1
Relevant Studies. There have been several reviews over the past decades that have looked at different lifestyle intervention for prevention of GDM. The majority of these reviews included primarily Caucasian women with interventions that vary in terms of delivery and outcomes, but a common conclusion is that quality of studies is low. Different RCTs have looked at diet intervention only, physical activity or a combination of both diet and physical intervention, and the use drug intervention with different outcomes not limited to GDM.
Sample 1
Relevant Studies. Consultant will summarize and depict relevant content from State and local planning studies which may or may not include the following:  City of Bend Comprehensive Plan  Deschutes County Comprehensive Plan  Local Transportation System PlansLocal Utility Master Plans  2013 Bend Municipal Airport Master Plan  Current Signed Bend Municipal Airport Layout PlanOregon Aviation Plan (OAP) – 2007/2013 Economic Update
Sample 1

Related to Relevant Studies

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Trials The Ship shall run the following test and trials: (1) Harbour Acceptance Tests, including setting to work of the various equipment;

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Regulatory Investigations TCI and TLIC agree to cooperate fully in any insurance or judicial regulatory investigation or proceeding arising in connection with Contracts distributed under this Agreement. TCI and TLIC further agree to cooperate fully in any securities regulatory inspection, inquiry, investigation or proceeding or any judicial proceeding with respect to TLIC, TCI, their affiliates and their representatives to the extent that such inspection, inquiry, investigation or proceeding or judicial proceeding is in connection with Contracts distributed under this Agreement. Without limiting the foregoing: (a) TCI will be notified promptly of any customer complaint or notice of any regulatory inspection, inquiry investigation or proceeding or judicial proceeding received by TLIC with respect to TCI or any representative or which may affect TLIC’s issuance of any Contracts marketed under this Agreement; and (b) TCI will promptly notify TLIC of any customer complaint or notice of any regulatory inspection, inquiry, investigation or judicial proceeding received by TCI or any representative with respect to TLIC or its affiliates in connection with any Contracts distributed under this Agreement. In the case of a customer complaint, TCI and TLIC will cooperate in investigating such complaint and shall arrive at a mutually satisfactory response.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!